Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Cited by (1,004)

Items 201–300 of 1,004

1. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
   Cameron Herberts, Andrew J. Murtha, Simon Yuen Fai Fu, Gang Wang, Elena Schönlau, Hui Xue, Dong Lin, Anna Gleave, Steven Yip, Arkhjamil Angeles et al. · 2020 · European Urology
2. Molecular alterations in meningioma: prognostic and therapeutic perspectives
   Cristina Birzu, Matthieu Peyre, Felix Sahm · 2020 · Current Opinion in Oncology
3. Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities
   Maxwell Roger Lloyd, Laura M. Spring, Aditya Bardia, Seth A. Wander · 2021 · Clinical Cancer Research
4. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
   Icro Meattini, Carlotta Becherini, Saverio Caini, Charlotte Elizabeth Coles, Javier Cortés, Giuseppe Curigliano, Evandro de Azambuja, Clare M. Isacke, Nadia Harbeck, Orit Kaidar‐Person et al. · 2024 · The Lancet Oncology
5. Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing
   Guan‐Tian Lang, Yi‐Zhou Jiang, Jinxiu Shi, Fan Yang, Xiaoguang Li, Yu‐Chen Pei, Chenhui Zhang, Ding Ma, Yi Xiao, Peng-Chen Hu et al. · 2020 · Nature Communications
6. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
   Thomas Grinda, Natacha Joyon, Amélie Lusque, Sarah Lefèvre, Laurent Arnould, Frederique Madeleine Penault-Llorca, Gaëtan Marie MacGrogan, Isabelle Treilleux, Anne Vincent‐Salomon, Juliette Haudebourg et al. · 2021 · npj Breast Cancer
7. Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma
   Alexandra Lahtinen, Kari Lavikka, Anni Virtanen, Yilin Li, Sanaz Jamalzadeh, Aikaterini Skorda, Anna Røssberg Lauridsen, Kaiyang Zhang, Giovanni Marchi, Veli‐Matti Isoviita et al. · 2023 · Cancer Cell
8. The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
   Qinglong Ma, Wenyang Zhang, Kongming Wu, Lei Shi · 2025 · Molecular Cancer
9. Drug‐induced peripheral oedema: An aetiology‐based review
   Bérenger Largeau, Jean‐Luc Cracowski, Céline Lengellé, Bénédicte Sautenet, A.‐P. Jonville‐Béra · 2021 · British Journal of Clinical Pharmacology
10. Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
    Senthil Damodaran, Fengmin Zhao, Dustin A. Deming, Edith Peterson Mitchell, John J. Wright, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry Rubinstein, David R. Patton et al. · 2022 · Journal of Clinical Oncology
11. PI3K inhibitors in thrombosis and cardiovascular disease
    Tom N. Durrant, Ingeborg Hers · 2020 · Clinical and Translational Medicine
12. The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis
    Cedric Tehranian, Laura Fankhauser, Patrick N. Harter, Colin D.H. Ratcliffe, Pia Susann Zeiner, Julia M. Messmer, Dirk C. Hoffmann, Katharina Frey, Dana Westphal, Michael W. Ronellenfitsch et al. · 2021 · Neuro-Oncology
13. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
    Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd Lilleng Gammelgaard, Monique F. Hundebøl, Kamila K. Kaminska, Lene E. Johansen, Martin Bak et al. · 2021 · Nature Communications
14. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
    David B. Page, Harry D. Bear, Sangeetha Prabhakaran, Margaret Elena Gatti-Mays, Alexandra Thomas, Erin Frances Cobain, Heather L. McArthur, Justin Micah Balko, Sofia R. Gameiro, Rita Nanda et al. · 2019 · npj Breast Cancer
15. The immunomodulatory effects of endocrine therapy in breast cancer
    Huanhuan Huang, Jun Zhou, Hailong Chen, Jiaxin Li, Chao Zhang, Xia Jiang, Chao Ni · 2021 · Journal of Experimental & Clinical Cancer Research
16. CircSEMA4B inhibits the progression of breast cancer by encoding a novel protein SEMA4B-211aa and regulating AKT phosphorylation
    Xuehui Wang, Wei Jian, Qifeng Luo, Lin Fang · 2022 · Cell Death and Disease
17. Current perspectives and trend of computer-aided drug design: a review and bibliometric analysis
    Zhenhui Wu, Shupeng Chen, Yihao Wang, Fangyang Li, Huanhua Xu, Maoxing Li, Yingjian Zeng, Zhenfeng Wu, Yue Gao · 2024 · International Journal of Surgery
18. Pathway‐level mutational signatures predict breast cancer outcomes and reveal therapeutic targets
    Máté Posta, Balázs Győrffy · 2025 · British Journal of Pharmacology
19. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
    Sara M. Tolaney, Arlene Chan, Katarína Petráková, Suzette Delaloge, Mario Campone, Hiroji Iwata, Parvin F. Peddi, Peter Andrew Kaufman, Elisabeth de Kermadec, Qianying Liu et al. · 2023 · Journal of Clinical Oncology
20. PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer
    Chunfang Hao, Yunchu Wei, Wenjing Meng, Jie Zhang, Xiaonan Yang · 2024 · Cancer Treatment Reviews
21. Lobular Breast Cancer: A Review
    Natalie Wilson, Alastair J. Ironside, Anna Diana, Olga Oikonomidou · 2021 · Frontiers in Oncology
22. Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
    Priyanka Sharma, Vandana Gupta Abramson, Anne P. O’Dea, Lauren Elizabeth Nye, Ingrid A. Mayer, Harsh B. Pathak, Marc Steven Hoffmann, Shane Richard Stecklein, Manana Elia, Sharon Lewis et al. · 2021 · Clinical Cancer Research
23. Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives
    Chikashi Watase, Sho Shiino, Tatsunori Shimoi, Emi Noguchi, Tomoya Kaneda, Yusuke Yamamoto, Kan Yonemori, Shin Takayama, Akihiko Suto · 2021 · Cancers
24. Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
    Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer, Vincent van der Noort, Astrid C P Swinkels, Hedwig M. Blommestein, Cristina Guerrero Páez, Linda Mol, Aart Beeker, Karin J. Beelen et al. · 2024 · Nature
25. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
    Hitisha Patel, Nianjun Tao, Kyung-Min Lee, Mariela Huerta-Rosario, Heike Arlt, Tara L. Mullarkey, Steven M. Troy, Carlos L. Arteaga, Teeru Bihani · 2019 · Breast Cancer Research
26. Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and Progression
    Esther Louise Moss, Diviya N. Gorsia, Anna Collins, Pavandeep Sandhu, Nalini Foreman, Anupama Gore, Joey Wood, Christopher D. Kent, Lee Silcock, David S. Guttery · 2020 · Cancers
27. The emerging role of PI3K inhibitors for solid tumour treatment and beyond
    Carmen Belli, Matteo Repetto, Santosh Kumar Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano · 2023 · British Journal of Cancer
28. Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
    Giacomo Barchiesi, Marco Mazzotta, Eriseld Krasniqi, Laura Pizzuti, Daniele Marinelli, Elisabetta Maria Capomolla, Domenico Sergi, Antonella Amodio, Clara Natoli, Teresa Gamucci et al. · 2020 · International Journal of Molecular Sciences
29. STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts
    2023
30. Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors
    Maria Vittoria Dieci, Federica Miglietta, Gaia Griguolo, Valentina Guarneri · 2020 · Cancer Treatment Reviews
31. Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
    G Morin, Caroline Degrugillier-Chopinet, Marie Vincent, Antoine Fraissenon, H. Aubert, Célia Chapelle, Clément Hoguin, François Dubos, Benoit Catteau, Florence Petit et al. · 2022 · The Journal of Experimental Medicine
32. The mutational landscape of the SCAN‐B real‐world primary breast cancer transcriptome
    Christian Brueffer, Sergii Gladchuk, Christof Winter, Johan Vallon‐Christersson, Cecilia Hegardt, Jari Häkkinen, Anthony M. George, Yilun Chen, Anna Ehinger, Christer Larsson et al. · 2020 · EMBO Molecular Medicine
33. First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors
    Robert McLeod, Rajiv Kumar, Dionysis Papadatos-Pastos, Joaquı́n Mateo, Jessica S. Brown, Alvaro Ingles Garces, Ruth R. Ruddle, Shaun Decordova, Simone Jueliger, Roberta Ferraldeschi et al. · 2020 · Clinical Cancer Research
34. SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
    Alexander Edward Dela Cruz Drilon, Manish R. Sharma, Melissa Lynne Johnson, Timothy Anthony Yap, Shirish M. Gadgeel, Dale L. Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed et al. · 2023 · Cancer Discovery
35. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
    Maria M Zlobinsky Rubinstein, David Michael Hyman, Imogen Caird, Helen H. Won, Krysten Soldan, Kenneth Seier, Alexia E. Iasonos, William P. Tew, Roisin Eilish O'Cearbhaill, Rachel Nicole Grisham et al. · 2019 · Cancer
36. Accelerating precision medicine in metastatic prostate cancer
    Joaquı́n Mateo, Rana R. McKay, Wassim M. Abida, Rahul Raj Aggarwal, Joshi J. Alumkal, Ajjai Shivaram Alva, Felix Yi-Chung Feng, Xin Yuan Gao, Julie Nicole Graff, Maha Hussain et al. · 2020 · Nature Cancer
37. Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma
    Jad Chahoud, Frederico O. Gleber‐Netto, Barrett Z. McCormick, Priya Rao, Xin Lü, Ming Guo, Maggaret B. Morgan, Randy Aaron Chu, Magaly Martínez‐Ferrer, Agda Karina Eterovic et al. · 2021 · Clinical Cancer Research
38. Risk and prognostic factors of breast cancer with liver metastases
    Lei Ji, Lei Cheng, Xiu-Zhi Zhu, Yu Gao, Lei Fan, Zhonghua Wang · 2021 · BMC Cancer
39. PI3K functions as a hub in mechanotransduction
    Mickaël Di‐Luoffo, Zacchari Ben Meriem, Pauline M. Lefebvre, Morgan Delarue, Julie Guillermet‐Guibert · 2021 · Trends in Biochemical Sciences
40. PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials
    Mirko K. Fillbrunn, James Signorovitch, Fabrice André, Iris Wang, Inés Lorenzo, Antonia Ridolfi, Jinhee Park, Akanksha Dua, Hope S. Rugo · 2022 · BMC Cancer
41. Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches
    Farah Raheem, Suganya Arunachalam Karikalan, Felipe Batalini, Aya El Masry, Lida A. Mina · 2023 · International Journal of Molecular Sciences
42. The landscape of drug sensitivity and resistance in sarcoma
    Ahmad Al Shihabi, Peyton J. Tebon, Huyen Thi Lam Nguyen, Jomjit Chantharasamee, Sara Sartini, Ardalan Davarifar, Alexandra Y Jensen, Miranda B. Diaz-Infante, Hannah Cox, Alfredo Enrique Gonzalez et al. · 2024 · Cell stem cell
43. Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
    Vincenza Caputo, Fortunato Ciardiello, Carminia Maria Della Corte, Giulia Martini, Teresa Troiani, Stefania Napolitano · 2023 · Exploration of Targeted Anti-tumor Therapy
44. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
    Maxwell Roger Lloyd, Komal L. Jhaveri, Kevin M. Kalinsky, Aditya Bardia, Seth Andrew Wander · 2024 · Nature Reviews Clinical Oncology
45. Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
    Zhen Li, Wei Zou, Ji Zhang, Yunjiao Zhang, Qi Xu, Siyuan Li, Ceshi Chen · 2020 · Frontiers in Pharmacology
46. U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
    Shaily Arora, Preeti Narayan, Christy L. Osgood, Suparna Bonthala Wedam, Tatiana Michelle Prowell, Jennifer J. Gao, Mirat Shah, Danielle Krol, Sakar Wahby, Melanie Royce et al. · 2021 · Clinical Cancer Research
47. Updates on breast biomarkers
    Saleh N. Najjar, Kimberly H. Allison · 2022 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
48. Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
    Felipe Batalini, Niya Xiong, Nabihah Tayob, Madeline M. Polak, Julia Eismann, Lewis C. Cantley, Geoffrey Ira Shapiro, Viktor A. Adalsteinsson, Eric P. Winer, Panagiotis A. Konstantinopoulos et al. · 2022 · Clinical Cancer Research
49. Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology
    Kinnersley, Ben, Sud, Amit, Everall, Andrew, Cornish, Alex J., Chubb, Daniel, Culliford, Richard, Gruber, Andreas J., Lärkeryd, Adrian, Mitsopoulos, Costas, Wedge, David et al. · 2024 · Nature Genetics
50. The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice
    Anouk K. M. Claessens, Khava I. E. Ibragimova, Sandra M. E. Geurts, Monique E.M.M. Bos, Frans Erdkamp, Vivianne C. G. Tjan‐Heijnen · 2020 · Critical Reviews in Oncology/Hematology
51. Update on prognostic and predictive biomarkers of breast cancer
    Yanjun Hou, Yan Shen Peng, Zaibo Li · 2022 · Seminars in Diagnostic Pathology
52. Liquid biopsy into the clinics: Current evidence and future perspectives
    Myrto A Boukovala, Christoph Benedikt Westphalen, Victoria Probst · 2024 · The Journal of Liquid Biopsy
53. Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
    Rossi, Valentina, Berchialla, Paola, Giannarelli, Diana, Nisticò, Cecilia, Ferretti, Gianluigi, Gasparro, Simona, Russillo, Michelangelo, Catania, Giovanna, Vigna, Leonardo, Mancusi, Rossella Letizia et al. · 2019 · Cancers
54. Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities
    Claire Xin Sun, Paul M Daniel, Gabrielle Bradshaw, Hui Shi, Melissa Loi, Nicole J. Chew, Sarah Parackal, Vanessa Tsui, Yuqing Liang, Mateusz Koptyra et al. · 2023 · Cancer Cell
55. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations
    Andreas S. Varkaris, Ferran Fece de la Cruz, Elizabeth E. Martin, Bryanna L. Norden, Nicholas J. Chevalier, Allison M. Kehlmann, Ignaty Leshchiner, Haley Barnes, Sara Ehnstrom, Anastasia-Maria Stavridi et al. · 2023 · Cancer Discovery
56. Theranostic Advances in Vascular Malformations
    Valérie Dekeuleneer, Emmanuel Seront, An Van Damme, Laurence Myriam Boon, Miikka Vikkula · 2020 · Journal of Investigative Dermatology
57. Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
    Nan Jin, Bhumsuk Keam, Janice Cho, Michelle J. Lee, Hye Ryun Kim, Hayarpi Torosyan, Natalia Jura, Patrick K.S. Ng, Gordon B. Mills, Hua Li et al. · 2021 · Journal of Clinical Investigation
58. Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
    Soma Ghosh, Pooja Anil Shah, Faye M. Johnson · 2022 · International Journal of Molecular Sciences
59. Imaging in metastatic breast cancer, CT, PET/CT, MRI, WB-DWI, CCA: review and new perspectives
    Dione Lother, Marie Robert, Elliot Elwood, Sam S. Smith, Nina Tunariu, Stephen R.D. Johnston, Marina Parton, Basrull Bhaludin, Thomas Millard, Kate Downey et al. · 2023 · Cancer Imaging
60. AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
    Amy E. Schade, Naiara Perurena, Yoona Yang, Carrie L. Rodriguez, Anjana Krishnan, Alycia Gardner, Patrick Loi, Yilin Xu, Van T.M. Nguyen, Gerald M. Mastellone et al. · 2024 · Nature
61. Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer
    Vassilis Aggelis, Stephen R.D. Johnston · 2019 · Drugs
62. Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
    Javier Pascual, Joline S.J. Lim, Iain R. Macpherson, Anne Caroline Armstrong, Alistair E. Ring, Alicia F. C. Okines, Rosalind J. Cutts, María Teresa Herrera-Abreu, Isaac García-Murillas, Alex Pearson et al. · 2020 · Cancer Discovery
63. Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
    Tereza Vaclová, Ursula Grazini, Lewis S. C. Ward, Daniel J. O’Neill, Aleksandra A. Markovets, Xiangning Huang, Juliann Chmielecki, Ryan James Hartmaier, Kenneth Stephen Thress, Paul D. Smith et al. · 2021 · Nature Communications
64. Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status
    Teesha D. Downton, Fiona H. Zhou, Davendra Segara, Rinath M. Jeselsohn, Elgene Lim · 2022 · Drug Design Development and Therapy
65. Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors
    Kevin Chen, Misty Dawn Shields, Pradeep S. Chauhan, Ricardo J. Ramirez, Peter K. W. Harris, Melissa Andrea Reimers, Jose Pedro Zevallos, Andrew A. Davis, Bruna Pellini, Aadel A. Chaudhuri · 2021 · Molecular Diagnosis & Therapy
66. Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
    Claudette Falato, Francesco Schettini, Tomás Pascual, Fara Brasó‐Maristany, Aleix Prat · 2022 · Cancer Treatment Reviews
67. Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs
    Christopher M. Booth, Elizabeth A. Eisenhauer, Bishal Gyawali, Ian F. Tannock · 2023 · Journal of Clinical Oncology
68. Landscape of circulating tumour DNA in metastatic breast cancer
    Andrew A. Davis, Saya Liz Jacob, Lorenzo Gerratana, Ami N. Shah, Firas Wehbe, Neelima Katam, Qiang Zhang, Lisa Flaum, Kalliopi P. Siziopikou, Leonidas C. Platanias et al. · 2020 · EBioMedicine
69. New drug approvals for 2019: Synthesis and clinical applications
    Shuo Yuan, Bin Yu, Hong‐Min Liu · 2020 · European Journal of Medicinal Chemistry
70. Understanding genomics and the immune environment of penile cancer to improve therapy
    Ahmet Murat Aydın, Jad Chahoud, Jacob J. Adashek, Mounsif Azizi, Anthony Martin Magliocco, Jeffrey S. Ross, Andrea Necchi, Philippe E. Spiess · 2020 · Nature Reviews Urology
71. CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
    Michela Roberto, Antonio Astone, Andrea Botticelli, Luisa Carbognin, Alessandra Cassano, Giuliana D’Auria, Agnese Fabbri, Alessandra Fabi, Teresa Gamucci, Eriseld Krasniqi et al. · 2021 · Cancers
72. Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis
    Andrea P. Espejo Freire, Andrew Elliott, Andrew Eric Rosenberg, Philippos Apolinário Costa, Priscila Barreto‐Coelho, Emily Jonczak, Gina Z. D’Amato, Ty K. Subhawong, Junaid Arshad, Julio Alexander Díaz-Pérez et al. · 2021 · Cancers
73. PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications
    Atish Dipankar Choudhury · 2022 · The Prostate
74. Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations
    Kaitlyn Zenner, Chi Vicky Cheng, Dana M. Jensen, Andrew E. Timms, Giridhar M. Shivaram, Randall A. Bly, Sheila N. Ganti, Kathryn B. Whitlock, William B. Dobyns, Jonathan A. Perkins et al. · 2019 · JCI Insight
75. Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer
    Marios Papadimitriou, Anastasia Pazaiti, Konstantinos Iliakopoulos, Mariam Markouli, Vasiliki Michalaki, CHRISTOS A. PAPADIMITRIOU · 2022 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
76. Obesity-associated changes in molecular biology of primary breast cancer
    Ha-Linh Nguyen, Tatjana Geukens, Marion Maetens, Samuel A. J. R. Aparicio, Ayse Bassez, Åke Borg, Jane E. Brock, Annegien Broeks, Carlos Caldas, Fátima Cardoso et al. · 2023 · Nature Communications
77. Small-molecule agents for cancer immunotherapy
    Fang Wang, Kai Fu, Yujue Wang, Can Pan, Xue‐Ping Wang, Zeyu Liu, Chuan Yang, Ying Yi Zheng, Xiaopeng Li, Yu Lu et al. · 2023 · Acta Pharmaceutica Sinica B
78. The Landscape of PIK3CA Mutations in Colorectal Cancer
    Ioannis A. Voutsadakis · 2021 · Clinical Colorectal Cancer
79. Circulating Free DNA and Its Emerging Role in Autoimmune Diseases
    Patricia Mondelo‐Macía, Patricia Garrido Castro, Adrián Castillo‐García, Laura Muinelo‐Romay, Roberto Díaz‐Peña · 2021 · Journal of Personalized Medicine
80. INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer
    Samuel J. Rodgers, Lisa M. Ooms, Viola M. J. Oorschot, Ralf B. Schittenhelm, Elizabeth V. Nguyen, Sabryn A. Hamila, Natalie K. Rynkiewicz, Rajendra Gurung, Matthew J. Eramo, Absorn Sriratana et al. · 2021 · Nature Communications
81. PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
    Aryana R. Rasti, Amy Guimarães-Young, Farrah Mikhail Datko, Virginia F. Borges, Dara L. Aisner, Elena I. Shagisultanova · 2022 · JCO Precision Oncology
82. Genomic Characterization of HPV-related and Gastric-type Endocervical Adenocarcinoma: Correlation With Subtype and Clinical Behavior
    Anjelica Hodgson, Brooke E. Howitt, Kay J. Park, Neal Ian Lindeman, Marisa R. Nucci, Carlos Parra‐Herran · 2019 · International Journal of Gynecological Pathology
83. AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway–Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B
    Jia Xu, Xufen Yu, Tiphaine C. Martin, Ankita Bansal, Kakit Cheung, Abigail Lubin, Elias Stratikopoulos, Kaitlyn M. Cahuzac, Li Wang, Ling Xie et al. · 2021 · Cancer Discovery
84. Random Forest Modelling of High-Dimensional Mixed-Type Data for Breast Cancer Classification
    Jelmar Quist, Lawson Taylor, Johan Staaf, Anita E. Grigoriadis · 2021 · Cancers
85. Low-dose mono(2-ethylhexyl) phthalate promotes ovarian cancer development through PPARα-dependent PI3K/Akt/NF-κB pathway
    Jing Leng, Hongyi Li, Yuequn Niu, Kelie Chen, Xiaoyu Yuan, Hanwen Chen, Zhiqin Fu, Lihuan Zhang, Fang Wang, Chaoyi Chen et al. · 2021 · The Science of The Total Environment
86. Targeted and cytotoxic inhibitors used in the treatment of breast cancer
    Robert Jr. Roskoski · 2024 · Pharmacological Research
87. Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
    Jason Schick, Raquel P. Ritchie, Carolina Baraldi A. Restini · 2021 · Breast Cancer Basic and Clinical Research
88. Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
    Peter Stephen Savas, Louisa Lisa Lo, Stephen James Luen, Elizabeth F. Blackley, Jason Callahan, Kate Moodie, Courtney T. van Geelen, Yi-An Ko, Chen-Fang Weng, Lironne Wein et al. · 2022 · Cancer Discovery
89. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
    Hope S. Rugo, Florence Lerebours, Eva M. Ciruelos, Pamela R. Drullinsky, Manuel Ruíz‐Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric et al. · 2024 · The Lancet Oncology
90. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review
    Maike J.M. Uijen, Gerben Lassche, Adriana C. H. van Engen–van Grunsven, Yuichiro Tada, Gerald W.C.T Verhaegh, Jack A. Schalken, C.M.L. Driessen, Carla M.L. van Herpen · 2020 · Cancer Treatment Reviews
91. PTEN and Other PtdIns(3,4,5)P3 Lipid Phosphatases in Breast Cancer
    Mariah P. Csolle, Lisa M. Ooms, Antonella Papa, Christina Anne Mitchell · 2020 · International Journal of Molecular Sciences
92. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
    Seock‐Ah Im, Alessandra Gennari, Y.H. Park, Jae Hyoung Kim, Zeping Jiang, Sameer Gupta, Trinugroho Heri Fadjari, K. Tamura, M.Y. Mastura, Maria Luisa T. Abesamis-Tiambeng et al. · 2023 · ESMO Open
93. Neuroendocrine breast carcinoma: a rare but challenging entity
    Elena Trevisi, Anna La Salvia, Lorenzo Daniele, Maria Pia Brizzi, Gaetano De Rosa, Giorgio V. Scagliotti, Massimo Di Maïo · 2020 · Medical Oncology
94. Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer
    Hsing‐Ju Wu, Pei‐Yi Chu · 2021 · International Journal of Molecular Sciences
95. Current and Developing Liquid Biopsy Techniques for Breast Cancer
    Hsing‐Ju Wu, Pei‐Yi Chu · 2022 · Cancers
96. Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
    Chiara Corti, Carmine De Angelis, Giampaolo Bianchini, Luca Malorni, Mario Giuliano, Erika Paige Hamilton, Rinath M. Jeselsohn, Komal L. Jhaveri, Giuseppe Curigliano, Carmen Criscitiello · 2023 · Cancer Treatment Reviews
97. Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Samitha Andrahennadi, Amer Sami, Mita Manna, Mehrnoosh Pauls, Shahid Ahmed · 2021 · Current Oncology
98. Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
    Irina Palacín-Aliana, Noemí Garcia‐Romero, Adriá Asensi-Puig, Josefa Carrión-Navarro, Víctor González‐Rumayor, Ángel Ayuso‐Sacido · 2021 · Biomedicines
99. A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer
    Gary Middleton, Helen L. Robbins, Fabrice André, Charles Swanton · 2021 · Annals of Oncology
100. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients
     Dana W.Y. Tsui, Michael L. Cheng, Maha Shady, Julie L. Yang, Dennis P. Stephens, Helen H. Won, Preethi Srinivasan, Kety H. Huberman, Fanli Meng, Xiaohong Jing et al. · 2021 · Genome Medicine